Eribulin for Advanced Breast Cancer: A Drug Evaluation

Eribulin is a synthetic microtubule dynamics inhibitor that was developed from a marine natural product halichondrin B. It exhibited in vitro and in vivo activities against a wide number of malignancies. A number of advanced phase trials showed improved survival following eribulin treatment in pretr...

Descripción completa

Detalles Bibliográficos
Autor principal: Shablak, Alaaeldin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Breast Cancer Society 2013
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3625759/
https://www.ncbi.nlm.nih.gov/pubmed/23593076
http://dx.doi.org/10.4048/jbc.2013.16.1.12
_version_ 1782266123711938560
author Shablak, Alaaeldin
author_facet Shablak, Alaaeldin
author_sort Shablak, Alaaeldin
collection PubMed
description Eribulin is a synthetic microtubule dynamics inhibitor that was developed from a marine natural product halichondrin B. It exhibited in vitro and in vivo activities against a wide number of malignancies. A number of advanced phase trials showed improved survival following eribulin treatment in pretreated advanced breast cancer patients. This review provides an overview of the background to the therapeutic use of eribulin in oncology, including its pharmacology, pharmacokinetics, clinical efficacy, safety, and potential economic factors.
format Online
Article
Text
id pubmed-3625759
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Korean Breast Cancer Society
record_format MEDLINE/PubMed
spelling pubmed-36257592013-04-16 Eribulin for Advanced Breast Cancer: A Drug Evaluation Shablak, Alaaeldin J Breast Cancer Review Article Eribulin is a synthetic microtubule dynamics inhibitor that was developed from a marine natural product halichondrin B. It exhibited in vitro and in vivo activities against a wide number of malignancies. A number of advanced phase trials showed improved survival following eribulin treatment in pretreated advanced breast cancer patients. This review provides an overview of the background to the therapeutic use of eribulin in oncology, including its pharmacology, pharmacokinetics, clinical efficacy, safety, and potential economic factors. Korean Breast Cancer Society 2013-03 2013-03-31 /pmc/articles/PMC3625759/ /pubmed/23593076 http://dx.doi.org/10.4048/jbc.2013.16.1.12 Text en © 2013 Korean Breast Cancer Society. All rights reserved. http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Shablak, Alaaeldin
Eribulin for Advanced Breast Cancer: A Drug Evaluation
title Eribulin for Advanced Breast Cancer: A Drug Evaluation
title_full Eribulin for Advanced Breast Cancer: A Drug Evaluation
title_fullStr Eribulin for Advanced Breast Cancer: A Drug Evaluation
title_full_unstemmed Eribulin for Advanced Breast Cancer: A Drug Evaluation
title_short Eribulin for Advanced Breast Cancer: A Drug Evaluation
title_sort eribulin for advanced breast cancer: a drug evaluation
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3625759/
https://www.ncbi.nlm.nih.gov/pubmed/23593076
http://dx.doi.org/10.4048/jbc.2013.16.1.12
work_keys_str_mv AT shablakalaaeldin eribulinforadvancedbreastcanceradrugevaluation

Ejemplares similares